Medscape and ACC Centers of Excellence

MedScape and ACC

The ACC has collaborated with Medscape to create two Centers of Excellence on the topics of Cardiovascular Risk Reduction and Heart Failure. This collaboration will expand the reach of expert information, including best practices in CV medicine, to improve patient care.

December 1, 2021
Beyond Bone Health: Does Vitamin D Have a Role in Cancer, CVD, and COVID?
Pam R. Taub, MD, FACC, FASPC; JoAnn E. Manson, MD, DrPH, MACP; Michael F. Holick, MD, PhD
Hi. I'm Pam Taub. I'm a cardiologist and professor of medicine at UC San Diego.

November 2, 2021
Peripartum Cardiomyopathy Management: 5 Things to Know
Deirdre J Mattina, MD
The incidence of adverse pregnancy outcomes, particularly peripartum cardiomyopathy (PPCM), is on the rise in the United States.

October 18, 2021
Optimal Use of SGLT2 Inhibitors and GLP-1 Agonists: 5 Things to Know
Matthew J. Budoff, MD
For the first time in any trial of hypoglycemic therapy, the EMPA-REG OUTCOME study demonstrated a significant reduction in major adverse cardiovascular events (MACE).

October 5, 2021
Hypertrophic Cardiomyopathy: Do New Markers Enhance Risk-Stratification Models?
Tom Kai Ming Wang, MBChB, MD; Milind Desai, MD, MBA
Hypertrophic cardiomyopathy (HCM) is the most common form of hereditary heart disease, affecting 1 in 200-500 people.

August 25, 2021
Improving Cardiometabolic Health in the COVID-19 Era
Jay H. Shubrook, DO, FAAFP, FACOFP
Hi. I'm Jay Shubrook, a family physician, professor at Touro University of California, and a primary care diabetologist. I'm delighted to be here today to give a COVID update as it relates to cardiometabolic health.

July 26, 2021
Cancer Therapy and Myocardial Dysfunction: 5 Things to Know
Douglas J. Leedy, MD; Richard K. Cheng, MD, MSc; Sofia Carolina Masri, MD; Suma H. Konety, MD
In the United States, there are an estimated 17 million cancer survivors, a number projected to increase to 26 million by 2040.

June 30, 2021
2018 AHA/ACC Multisociety Cholesterol Guideline vs 2019 ESC/EAS Dyslipidemia Guidelines: 5 Things to Know
Andi Shahu, MD, MHS; David I. Feldman, MD, MPH; Erin D. Michos, MD, MHS, FACC, FAHA, FASE
Here are five notable similarities and differences between the AHA/ACC and ESC/EAS guidelines.

May 24, 2021
Cardiologists Should Be More Involved in Treating NAFLD/NASH
Seth J. Baum, MD, FACC, FAHA, FNLA, FASPC; Jay H. Shubrook, DO, FAAFP FACOFP
We know that NAFLD and its extension into NASH are significant contributors to disease and, at least in primary care, might be the most common cause of cryptogenic cirrhosis.

May 11, 2021
Tips for Navigating Prior Authorization and Out-of-Pocket Costs for HFrEF Medications
Larry A. Allen, MD, MHS; Sarah J. Sarni, BSN, BA
As clinicians, we know the importance of promptly initiating treatment for our patients with heart failure with reduced ejection fraction (HFrEF) to improve survival, rehospitalization, and medication adherence.

April 21, 2021
An Expert's Guide to Managing Familial Hypercholesterolemia
Seth J. Baum, MD, FACC, FAHA, FNLA, FASPC
One of the most important things to know about HeFH is that it's actually quite common, occurring in approximately 1 in every 200-250 people.

April 14, 2021
Do GLP-1 Agonists and SGLT2 Inhibitors Have a Role in HF Treatment?
Neelam Upadhyaya, MD; Ajay D. Rao, MD, MMSc
The management of patients with heart failure (HF) has taken an interesting and exciting turn thanks to studies demonstrating the positive effects and growing utilization of newer glucose-lowering therapies for reduction of HF outcomes — namely glucagon-like peptide 1 (GLP-1) agonists and oral sodium glucose cotransport 2 (SGLT2) inhibitors.

January 27, 2021
Antiplatelet Therapy: Where Do We Stand Now?
Sripal Bangalore, MD, MHA; Usman Baber, MD, MS
Welcome to this session, "Antiplatelet Therapy: Where Do We Stand Now?" This is Sripal Bangalore, interventional cardiologist and professor of medicine at New York University School of Medicine.

January 13, 2021
Does the Ketogenic Diet Benefit Patients With Heart Failure?
Kim L. Ho, BSc; John R. Ussher, PhD; Gary D. Lopaschuk, PhD
The ketogenic ("keto") diet, originally developed in the 1920s as an alternative treatment for pediatric epilepsy, remains a therapeutic strategy for a variety of conditions, including neurodegenerative diseases, diabetes, nonalcoholic fatty liver disease, cancer, and, most notably, weight loss.

November 23, 2020
CAC Scores, Lp(a), CRP: CV Screening in Real Life -- Who Really Needs It?
Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC; Matthew J. Budoff, MD
New American College of Cardiology/American Heart Association guidelines came out in 2018. They more strongly advocated for screening and recommended generally lower lipid targets than 2013.

November 10, 2020
Remote Monitoring Systems in Heart Failure: What's the Current Status?
Mary E. McClain, MSN; Katie M. Murphy, MBBCh, BAO; Brian W. Hardaway, MD
Hospitalization for heart failure (HF) marks a pivotal event in the disease course of our patients, one that carries a 1-year mortality rate of 25%.

October 7, 2020
Heart Failure With Preserved Ejection Fraction Management: 5 Things to Know
Daniel N. Silverman MD; Sheldon E. Litwin, MD; Ryan J. Tedford, MD
Patients with heart failure with preserved ejection fraction (HFpEF) represent approximately 50% of all HF cases.

September 10, 2020
Tips for Handling Polypharmacy and Medication Nonadherence in Patients With Heart Failure
Lynne M. Sylvia, PharmD; Robert L. Page II, PharmD, MSPH
Clinicians managing patients with heart failure (HF) won't be surprised that these patients take almost seven prescription medications per day, totaling around 10 doses a day.

August 28, 2020
What Do ISCHEMIA and CIAO Tell Us About CVD?
Pam R. Taub, MD, FACC, FASPC; Harmony R. Reynolds, MD
This interview will discuss the CIAO and ISCHEMIA trials.

August 6, 2020
Sodium Restriction in Heart Failure: What We Do and Don't Know
Author: Eloisa Colin-Ramirez, PhD; Justin Ezekowitz, MBBCh, MSc
This article offers an overview of what physicians know and still need to learn about sodium restriction and clinical outcomes of patients with HF over the long term.

July 16, 2020
SGLT2 Inhibitors Beyond Diabetes: A Team Effort in CVD and Renal Disease
Matthew J. Budoff, MD; Jay H. Shubrook, DO
This is a discussion about sodium-glucose cotransporter 2 (SGLT2) inhibitors and where they fit in cardiology versus primary care practice today.

June 23, 2020
Novel Lipid Therapies: 5 Things to Know
Alan P. Jacobsen, MB, BCh, BAO; Eamon Y. Duffy, MD, MBA; Seth S. Martin, MD, MHS
This article offers physicians five things to know about novel pharmacotherapies targeting low-density lipoprotein (LDL), lipoprotein a, and triglycerides (TG) to help prevent patients' risk of atherosclerotic cardiovascular disease (ASCVD).

May 28, 2020
Heart Failure Prevention Post-Myocardial Infarction:5 Things to Know
Musa A. Sharkawi, MBBCh; Ajar Kochar, MD, MHS
This article offers physicians five things to know about the prevention and management of HF in patients after MI.

January 28, 2020
Effecting Dietary Modifications in Patients: 5 Things to Know
Amit Khera, MD, MSc, FACC; Susan G. Rodder, MS, RDN, LD
This article offers physicians five things to know about effecting successful dietary modifications in patients.

December 11, 2019
2019 CVD Primary Prevention Guideline: 5 Things to Know
Erin D. Michos, MD, MHS; Andi Shahu, MD, MHS
To enhance patient care and lower the prevalence and incidence of CVD, the American College of Cardiology (ACC) and American Heart Association (AHA) published concise guideline recommendations for the primary prevention of CVD.

November 15, 2019
The Role of Non-statin Therapy for Secondary Prevention of ASCVD: Clinical Case
Salim S. Virani, MD, PhD, FACC; Xiaoming Jia, MD; Jay H. Shubrook, DO
Case Presentation: A 64-year-old woman sees her cardiologist for a routine follow-up visit after a second myocardial infarction (MI).

November 1, 2019
2018 Updated AHA/ACC Multisociety Cholesterol Guideline: 5 Things to Know
Neil J. Stone, MD, FACC; Scott M. Grundy MD, PhD
The updated 2018 AHA/ACC Multisociety Cholesterol Guideline further refined the secondary prevention category and expanded the scope of primary prevention to include all age groups. This piece offers five things to know about the 2018 AHA/ACC guideline.

October 16, 2019
Aspirin Recs Go Topsy-Turvy in New Guidelines: Now What?
Michael D. Miedema, MD, MPH; J. William McEvoy, MB BCh, MHS
ACC/AHA primary prevention guideline authors Bill McEvoy and Mike Miedema discuss practical aspects of aspirin use after its recent downgrade based on studies showing little to no benefit.

June 19, 2019
Cardiologists Must 'Get Up To Speed' on Treating Diabetes
Cardiologists currently see more patients with diabetes than do endocrinologists, according to a study presented at the 2019 Endocrine Society Annual Meeting in New Orleans. Despite these figures, many cardiovascular (CV) specialists report being poorly equipped to address diabetes with novel agents.

April 11, 2019
CVD Primary Prevention Guideline Puts Patients Center Stage
Salim S. Virani, MD, PhD, FACC; Donna K. Arnett, MSPH, PhD; Erin D. Michos, MD, MHS
Watch Writing Committee Members discuss the new Guideline for Primary Prevention of Cardiovascular Disease.

February 25, 2019
Medscape/ACC Survey Looks at CV Risk Factor Management
The Survey Sheds Light on How Cardiologists Currently Address Diet and Lifestyle, Hypertension, and Type 2 Diabetes in Their Patients.



Clinical Topics: Cardiovascular Care Team, Heart Failure and Cardiomyopathies, Prevention, Acute Heart Failure

Keywords: Heart Failure, Risk Reduction Behavior, Risk Factors, Primary Prevention


< Back to Listings